Population pharmacokinetics of orally administered mefloquine in healthy volunteers and patients with uncomplicated Plasmodium falciparum malaria

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 3, 2015, Pages 868-876

  Reuter, Stephanie E ^a   Upton, Richard N ^a   Evans, Allan M ^a   Navaratnam, Visweswaran ^b,c   Olliaro, Piero L ^d,e  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^b SCHOOL OF PHYSICS   (Malaysia)

^c TAYLOR S UNIVERSITY   (Malaysia)

^d UNICEF   (United States)

^e UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

P. falciparum; Pharmacometrics; PK

Indexed keywords

ARTESUNATE; MEFLOQUINE; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE;

ADULT; ANEMIA; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; CONVALESCENCE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG FORMULATION; DRUG HALF LIFE; ELIMINATION HALF-LIFE; FEMALE; HUMAN; MALARIA; MALARIA FALCIPARUM; MALE; MONTE CARLO METHOD; PROTEIN BINDING; VOLUME OF DISTRIBUTION; ADOLESCENT; CHEMISTRY; CONTROLLED STUDY; CROSSOVER PROCEDURE; MALARIA, FALCIPARUM; MIDDLE AGED; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PLASMA; RANDOMIZED CONTROLLED TRIAL; YOUNG ADULT;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTIMALARIALS; ARTEMISININS; CROSS-OVER STUDIES; FEMALE; HEALTHY VOLUNTEERS; HUMANS; MALARIA, FALCIPARUM; MALE; MEFLOQUINE; MIDDLE AGED; MONTE CARLO METHOD; PLASMA; YOUNG ADULT;

EID: 84928189676     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku430     Document Type: Article

References (29)

1. WHO. World Malaria Report. Geneva: WHO, 2011.
2. WHO. Guidelines for the Treatment of Malaria, 2nd edn. Geneva:WHO, 2010.
3. Nosten F, van Vugt M, Price R et al. Effects of artesunate-mefloquine combination on incidence of Plasmodium falciparum malaria and mefloquine resistance in western Thailand: a prospective study. Lancet 2000; 356: 297-302.
4. Palmer KJ, Holliday SM, Brogden RN. Mefloquine. A review of its antimalarial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1993; 45: 430-75.
5. Luxemburger C, van Vugt M, Slight Tet al. Early vomiting of mefloquine in children with malaria is not modified by the timing of antipyretic treatment. Trans R Soc Trop Med Hyg 1998; 92: 562-3.
6. Simpson JA, Price R, ter Kuile F et al. Population pharmacokinetics of mefloquine in patients with acute falciparum malaria. Clin Pharmacol Ther 1999; 66: 472-84.
7. WHO. Guidelines for the Treatment of Malaria. Geneva: WHO, 2006.
8. Price R, Simpson JA, Teja-Isavatharm P et al. Pharmacokinetics of mefloquine combined with artesunate in children with acute falciparum malaria. Antimicrob Agents Chemother 1999; 43: 341-6.
9. Boudreau EF, Fleckenstein L, Pang LWet al. Mefloquine kinetics in cured and recrudescent patients with acute falciparum malaria and in healthy volunteers. Clin Pharmacol Ther 1990; 48: 399-409.
10. Karbwang J, Back DJ, Bunnag D et al. A comparison of the pharmacokinetics of mefloquine in healthy Thai volunteers and in Thai patients with falciparum malaria. Eur J Clin Pharmacol 1988; 35: 677-80.
11. Looareesuwan S, White NJ, Warrell DA et al. Studies of mefloquine bioavailability and kinetics using a stable isotope technique: a comparison of Thai patients with falciparum malaria and healthy Caucasian volunteers. Br J Clin Pharmacol 1987; 24: 37-42.
12. Olliaro P, Ramanathan S, Vaillant M et al. Pharmacokinetics and comparative bioavailability of artesunate and mefloquine administered separately or as a fixed combination product to healthy volunteers and patients with uncomplicated Plasmodium falciparum malaria. J Bioequiv Availab 2010; 2: 59-66.
13. Krudsood S, Looareesuwan S, Tangpukdee N et al. New fixeddose artesunate-mefloquine formulation against multidrug-resistant Plasmodium falciparum in adults: a comparative phase IIb safety and pharmacokinetic study with standard-dose nonfixed artesunate plus mefloquine. Antimicrob Agents Chemother 2010; 54: 3730-7.
14. Lai CS, Nair NK, Mansor SM et al. An analytical method with a single extraction procedure and two separate high performance liquid chromatographic systems for the determination of artesunate, dihydroartemisinin and mefloquine in human plasma for application in clinical pharmacological studies of the drug combination. J Chromatogr B 2007; 857: 308-14.
15. Savic RM, Jonker DM, Kerbusch T et al. Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies. J Pharmacokinet Pharmacodyn 2007; 34: 711-26.
16. Ashley EA, Stepniewska K, Lindegardh N et al. Population pharmacokinetic assessment of a new regimen of mefloquine used in combination treatment of uncomplicated falciparum malaria. Antimicrob Agents Chemother 2006; 50: 2281-5.
17. Simpson J, Aarons L, Price R et al. The influence of body weight on the pharmacokinetics of mefloquine. Br J Clin Pharmacol 2002; 53: 337-8.
18. Charles BG, Blomgren A, Nasveld PE et al. Population pharmacokinetics of mefloquine in military personnel for prophylaxis against malaria infection during field deployment. Eur J Clin Pharmacol 2007; 63: 271-8.
19. Svensson US, Alin H, Karlsson MO et al. Population pharmacokinetic and pharmacodynamic modelling of artemisinin and mefloquine enantiomers in patients with falciparum malaria. Eur J Clin Pharmacol 2002; 58: 339-51.
20. 1-acid glycoprotein. Bioorg Med Chem 2008; 16: 3759-72.
21. Kremer JM, Wilting J, Janssen LH. Drug binding to human a-1-acid glycoprotein in health and disease. Pharmacol Rev 1988; 40: 1-47.
22. MacKichan JJ. Influence of protein binding and use of unbound (free) drug concentrations. In: Burten ME, Shaw LM, Schentag JJ et al., eds. Pharmacokinetics and Pharmacodynamics: Principles of Therapeutic Drug Monitoring. Baltimore, MD: Lippincott Williams & Wilkins, 2006; 82-120.
23. Voulgari F, Cummins P, Gardecki TI et al. Serum levels of acute phase and cardiac proteins after myocardial infarction, surgery, and infection. Br Heart J 1982; 48: 352-6.
24. Johnson JA. Influence of race or ethnicity on pharmacokinetics of drugs. J Pharm Sci 1997; 86: 1328-33.
25. Brocks DR, Mehvar R. Stereoselectivity in the pharmacodynamics and pharmacokinetics of the chiral antimalarial drugs. Clin Pharmacokinet 2003; 42: 1359-82.
26. Gimenez F, Pennie RA, Koren G et al. Stereoselective pharmacokinetics of mefloquine in healthy Caucasians after multiple doses. J Pharm Sci 1994; 83: 824-7.
27. Hellgren U, Jastrebova J, Jerling M et al. Comparison between concentrations of racemic mefloquine, its separate enantiomers and the carboxylic acid metabolite in whole blood serum and plasma. Eur J Clin Pharmacol 1996; 51: 171-3.
28. Pham YT, Nosten F, Farinotti R et al. Cerebral uptake of mefloquine enantiomers in fatal cerebral malaria. Int J Clin Pharmacol Ther 1999; 37: 58-61.
29. Vidrequin S, Gimenez F, Basco LK et al. Uptake of mefloquine enantiomers into uninfected and malaria-infected erythrocytes. Drug Metab Dispos 1996; 24: 689-91.